 |
|
|
| |
Barriers to Hepatitis C Virus Elimination in
Germany in Patients Receiving Opioid Substitution Therapy
|
| |
| |
AASLD 2020 virtual Nov 11-16
Reported by Jules Levin
H Hinrichsen1, P Buggisch2, H Heiken3, S Mauss4, B Weber5, MC Jung6, H Görne7, R Heyne8, D Hidde9, B Koenig9, M Bondin10, C Niederau11, H Wedemeyer12, T Berg131Centre for Gastroenterology and Hepatology, Kiel, Germany; 2ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany; 3Private practice, Hanover, Germany; 4Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 5Praxiszentrum Friedrichsplatz/Competence Center Addiction, Kassel, Germany; 6Liver Centre, Munich, Germany; 7MediZentrum Hamburg, Praxis für Suchtmedizin, Hamburg, Germany; 8Leberzentrum am Checkpoint, Berlin, Germany; 9AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany; 10AbbVie Inc., North Chicago, Illinois, United States; 11Private practice, Oberhausen, Germany; 12Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 13Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
|
| |
|
|
|
|
|
